Literature DB >> 22996104

Minimally invasive endometrial ablation device complications and use outside of the manufacturers' instructions.

Jill Brown1, Ken Blank.   

Abstract

OBJECTIVE: To review the U.S. Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience database for reports describing serious adverse events and adverse events reports describing use outside of the manufacturers' labeled instructions for the five FDA-approved minimally invasive endometrial ablation devices.
METHODS: We queried the Manufacturer and User Facility Device Experience database for reports of device malfunction, patient injury, or death reported for each device from January 1, 2005 to December 31, 2011. We reviewed U.S. reports individually for annotations of patient injury or death and tabulated the reports by type of injury and device. We identified nine categories of serious injury (death, sepsis or bacteremia, intra-abdominal abscess, uterine rupture, thermal bowel injury, mechanical bowel injury, transmural uterine thermal injury, urologic injury, and lower genital tract or skin burns) and noted all reports citing device use outside of the manufacturers' labeled instructions. We also identified reports of hysterectomy or bowel resection attributable to an adverse event.
RESULTS: Serious adverse events, including bowel injury (n=128), sepsis or bacteremia (n=47), intra-abdominal abscess (n=18), urologic injury (n=2), and uterine rupture (n=1) were reported. Death was also reported (n=4). Eight percent (66 of 829) of serious adverse events reports cited use outside of the manufacturers' labeled instructions, as did 7.3% (6 of 82) of reports citing need for hysterectomy and 8.7% (9 of 103) of reports of bowel resection.
CONCLUSION: The findings from the Manufacturer and User Facility Device Experience database highlight the potential risk of serious complications related to endometrial ablation and underscore the importance of training in correct device use and familiarity with the manufacturer's labeled instructions. LEVEL OF EVIDENCE: III.

Entities:  

Mesh:

Year:  2012        PMID: 22996104     DOI: 10.1097/AOG.0b013e31826af4fe

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

Review 1.  Ten-year literature review of global endometrial ablation with the NovaSure® device.

Authors:  Richard J Gimpelson
Journal:  Int J Womens Health       Date:  2014-03-11

2.  Efficacy and patient satisfaction after NovaSure and Minerva endometrial ablation for treating abnormal uterine bleeding: a retrospective comparative study.

Authors:  Constantine Scordalakes; Robert delRosario; Andrew Shimer; Russell Stankiewicz
Journal:  Int J Womens Health       Date:  2018-04-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.